866467-28-9 Usage
Molecular structure
A complex compound consisting of a naphthalene ring, a carboxamide group, and a cyclopenta[b]pyrrol-6-yl group.
Amino acid derivative
Includes an octahydro-1-(N-methyl-L-alanyl-3-methyl-L-valyl) group, which is derived from N-methyl-L-alanine and 3-methyl-L-valine.
Pharmaceutical applications
Potential use in the pharmaceutical and medical industries, possibly as a drug or as a component of drug development.
Biological activity
The complex structure of the compound suggests that it may have potential for biological activity.
Stereochemistry
The compound has a specific stereochemistry with 3aR, 6S, and 6aS configurations.
Octahydro group
The compound contains an octahydro group, indicating the presence of eight hydrogen atoms in the structure.
Check Digit Verification of cas no
The CAS Registry Mumber 866467-28-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,6,4,6 and 7 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 866467-28:
(8*8)+(7*6)+(6*6)+(5*4)+(4*6)+(3*7)+(2*2)+(1*8)=219
219 % 10 = 9
So 866467-28-9 is a valid CAS Registry Number.
866467-28-9Relevant articles and documents
Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold
Cohen, Frederick,Alicke, Bruno,Elliott, Linda O.,Flygare, John A.,Goncharov, Tatiana,Keteltas, Stephen F.,Franklin, Matthew C.,Frankovitz, Stacy,Stephan, Jean-Philippe,Tsui, Vickie,Vucic, Domagoj,Wong, Harvey,Fairbrother, Wayne J.
experimental part, p. 1723 - 1730 (2010/02/28)
A series of IAP antagonists based on an azabicyclooctane scaffold was designed and synthesized. The most potent of these compounds, 14b, binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domain of c-IAP1 with Ki values of 14
AZABICYCLO-OCTANE INHIBITORS OF IAP
-
Page/Page column 38, (2008/06/13)
The invention provides novel inhibitors of IAP that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula (I) in which X1 and X2 are independently O or S; L is a bond or -C(X3